MET and hepatocellular carcinoma: (3) Activation of pro-survival pathways: Hepatocyte growth factor (HGF) in EVs activates the HGF/c-MET/PI3K/AKT axis in hepatocellular carcinoma (HCC), driving resistance to sorafenib.